3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Glioma
4
Sarcoma
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumors Harboring NTRK Fusion
1
Sarcoma, Ewing
1
Interventions
pembrolizumab
243
Carboplatin
211
Pemetrexed
177
Cisplatin
131
Paclitaxel
113
Nivolumab
101
Docetaxel
87
osimertinib
85
durvalumab
78
Specimen Handling
56
atezolizumab
55
Gemcitabine
52
Drug Therapy
52
Magnetic Resonance Spectroscopy
50
Radiosurgery
48
Radiotherapy
47
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
34
Cetuximab
30
tislelizumab
29
amivantamab
22
Taxes
22
Platinum Compounds
20
Blood Specimen Collection
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
larotrectinib
×
1 year
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA
NCT06563999
2026-04-21
NUMER
Sun Yat-sen University
Phase 2
Recruiting
120 enrolled